Illumina
Illumina, Inc., a leading player in the genomics industry, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 1998, Illumina has revolutionised DNA sequencing and array-based solutions, making substantial contributions to genomic research and personalised medicine. The company’s core products include advanced sequencing systems, reagents, and bioinformatics tools, which are distinguished by their high throughput and accuracy. Illumina's innovative technologies have positioned it at the forefront of the market, enabling researchers and clinicians to unlock the complexities of the genome. With numerous accolades and a robust portfolio, Illumina continues to drive advancements in genomics, supporting initiatives in healthcare, agriculture, and environmental science. Its commitment to innovation and quality has solidified its reputation as a trusted partner in the life sciences sector.
DitchCarbon Score
How does Illumina's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Illumina's score of 66 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Illumina's reported carbon emissions
In 2022, Illumina, Inc. reported total greenhouse gas emissions of approximately 18,902,000 kg CO2e for Scope 1 and 21,137,000 kg CO2e for Scope 2, with no reported emissions for Scope 3. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its direct operations and value chain by 2050, using 2019 as the base year. Illumina has established near-term targets to reduce absolute Scope 1 and 2 emissions by 46% by 2030. Additionally, the company plans to increase its annual sourcing of renewable electricity from 0.6% in 2019 to 100% by 2030. For Scope 3 emissions, which include categories such as purchased goods and services, business travel, and employee commuting, Illumina also targets a 46% reduction by 2030. Long-term goals include a 90% reduction in both Scope 1 and 2 emissions and Scope 3 emissions by 2050, again using 2019 as the baseline. These commitments align with the Science Based Targets initiative (SBTi) and reflect Illumina's dedication to sustainability and climate action within the biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 6,317,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,165,000 | 00,000,000 | 00,000,000 | 0,000,000 | - | - |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Illumina is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
